Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek July 18, 2005 John Carey	Is Heart Surgery Worth It? Physicians are questioning whether bypasses and angioplasties necessarily prolong patients' lives.
The Motley Fool July 5, 2006 Glenn Brandys	FoxHollow's SilverHawk Won't Soar Cost, time, and competition are holding back the med-tech's device for treating artery disease. Investors, take note.
BusinessWeek June 9, 2009 John Carey	Giving Patients the Data They Need A growing effort by doctors, insurers, and politicians helps people make better-informed medical decisions
BusinessWeek July 18, 2005	A Coronary Conundrum Four medical experts weigh in on whether heart surgery prolongs patients' lives or only relieves suffering.
The Motley Fool March 29, 2007 Michael P. Cecil	Stents on Trial New study results could affect stent sales -- at least in the short term.
BusinessWeek September 9, 2010 Michelle Cortez	Coming Soon: Dissolvable Stents New stents from Abbott Labs and others appear to reduce the risk of blood clots
The Motley Fool May 4, 2007 Billy Fisher	In Search of New Prey at FoxHollow The medical device maker reported a 6% increase in revenues on a year-over-year basis for its first-quarter. Investors, take note.
The Motley Fool February 15, 2007 Billy Fisher	Taking FoxHollow's Pulse The medical-device maker gets a checkup from the market. Results were mixed, although the stock was trading down 4%.
Managed Care July 2003 Thomas Morrow	Drug-Eluting Stents To Transform Cardiovascular Medicine By reducing restenosis, these devices will save managed care money.
The Motley Fool October 31, 2006 Michael P. Cecil	An Opening for Plavix New data suggesting problems with drug-eluting stents may translate into more sales of the blood thinner Plavix and fewer sales of the stents. Investors, take note.
HBS Working Knowledge November 22, 2004 Martha Lagace	Does the Medical Industry Deliver Value? When the discussion turns to healthcare reform, we get sidetracked on issues such as soaring costs. The real issue is, what is the most effective way to treat a disease or condition?
American Family Physician December 15, 2001 Julia Tucker De Sanctis	Percutaneous Interventions for Lower Extremity Peripheral Vascular Disease Peripheral vascular disease is a common condition with variable morbidity affecting mostly men and women older than 50 years. More than 70 percent of patients diagnosed with the disease remain stable or improve with conservative management...
BusinessWeek October 29, 2007 Arlene Weintraub	Heart Trouble The tiny stent sparked a lucrative industry - and made Dr. Samin Sharma a star. Then questions arose about the device's safety and efficacy.
Nursing March 2009 Kate J. Morse	Focusing on the Surgical Patient with Cardiac Problems Learn about the latest guidelines for assessing cardiac risk and protecting his heart during noncardiac surgery.
The Motley Fool June 1, 2005 Stephen D. Simpson	Stent Wars: Revenge of the Bypass A new study supports a long-held belief that bypass surgery is better than using stents. What does it mean for stent makers and investors?
American Family Physician February 1, 2004	Peripheral Arterial Disease What is peripheral arterial disease?... What are the signs of PAD?... Who is at risk of getting PAD?... How does my doctor know I have PAD?... How is PAD treated?... Does PAD cause long-term problems?... etc.
Nurse Practitioner November 2011 Tracy Brazziel et al.	Stopping the Wave of PAD Early detection and diagnosis of atherosclerotic disease is imperative. Here, learn the risk factors, screening and diagnosis for this disease.
The Motley Fool December 13, 2006 Stephen Albainy-Jenei	The Latest Standpoint on Stents A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents. Investors, take note.
The Motley Fool August 4, 2006 Stephen D. Simpson	SilverHawk Flying Just Fine, Thanks With med-tech company FoxHollow Technologies, there is growth and risk in equal measure. Investors, take note.
Managed Care June 2006 Tom Pope	Hard to Curb Overuse of Drug-Eluting Stents Health plans find themselves paying for the latest and greatest stent without any control over usage. Even bare-metal stents may be overused.
Health July 2007 Curt Pesmen	Surgery to Avoid #3: Angioplasty A new study has found that heart medication is just as effective as this invasive surgery.
The Motley Fool March 31, 2010 Brian Orelli	How Do You Put a Price on Pain? Price controls could wreck havoc on expensive therapies that control pain.
BusinessWeek October 29, 2007 Arlene Weintraub	Medtronic's Uncertain Endeavor The drug-coated stent might have made up for Medtronic's recent product recall, but renewed scrutiny of the device has executives scaling back expectations
American Family Physician November 15, 2004 Mark H. Ebell	Prognosis for Patients Undergoing Coronary Angioplasty Several clinical decision rules have been developed and validated to estimate the likelihood of short-term, in-hospital complications such as death, myocardial infarction, and urgent coronary artery bypass graft surgery.
The Motley Fool November 10, 2006 Billy Fisher	FoxHollow Taken to the Cleaners The medical-device maker's reduced guidance leaves investors steamed.
BusinessWeek October 9, 2006 John Carey	"No One Wanted To Hear" Renu Virmani warned that, over time, some drug-coated stents could lead to fatal clots.
The Motley Fool February 21, 2007 Billy Fisher	Scorching Sales Growth at ev3 Profits should be arriving soon for this medical device maker. The medical breakthroughs already are. Investors, take note.
Chemistry World November 7, 2011 Kate McAlpine	Spotting Artery Damage Before a Heart Attack An international team of medical researchers has developed a way to perform a check up on an artery's physical structure and molecular markers of ill health by coupling a catheter with imaging technology.
Managed Care February 2007 Maggie Mahar	Why Market Competition Will Not Mend Our Health Care System Doctors have a saying: 'Half of what we know is wrong.' In which half is the conventional wisdom that competition is society's best hope for improving quality and controlling costs?
The Motley Fool June 30, 2011 Brian Orelli	Medical-Device Makers' Killer: Health-Care Inflation High prices have painted their targets.
American Family Physician April 1, 2001 Joan Bedinghaus	Coronary Artery Disease Prevention: What's Different for Women? Cardiovascular disease is the leading cause of death in women, as well as an important cause of disability, although many women and their physicians underestimate the risk...
BusinessWeek August 8, 2005 Amy Barrett	BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals.
American Family Physician July 15, 2003	Heart Attack: Warning Signs and Tips on Prevention What is a heart attack?... How do I know if I am having a heart attack?... What should I do If I think I am having a heart attack?... How can I avoid having a heart attack?
Health February 2007 Eric Steinmehl	The Latest Medial Breakthroughs for the Heart Last year's biggest medical advances are changing the face and future of your health. Here's what you need to know - now!
The Motley Fool February 27, 2006 Stephen D. Simpson	A Foxy Idea? Medical device maker Foxhollow is in an attractive niche, but management turnover is a reason for investors to worry.
The Motley Fool October 25, 2007 Brian Orelli	Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them?
American Family Physician April 15, 2003	Coronary Artery Disease: Reducing Your Risk What is coronary artery disease?... What causes CAD?... What can I do to lower my risk of CAD?
The Motley Fool December 29, 2006 Matthew Crews	FoxHollow: Scale Is Critical Can this medical-device maker be a long-term success, or is it just a one-hit wonder? Investors, take note.
The Motley Fool September 25, 2008 Brian Orelli	Uh-Oh, Stent Makers Drugs are just as good as stents.
Chemistry World August 22, 2013 Emma Eley	Next-generation vascular stents Scientists in the US and China have developed a biodegradable alloy for use in medical implants. The new alloy, called JDBM, mixes magnesium, neodymium, zinc and zirconium.
The Motley Fool September 29, 2006 Brian Lawler	Merck Likes FoxHollow The pharmaceutical giant signs another collaborative research agreement with the small-cap company. Investors, take note.
The Motley Fool December 13, 2006 Matthew Crews	Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies.
The Motley Fool March 27, 2008 Brian Orelli	Tougher Rules Could Help Stent Makers The FDA has finally issued draft guidance on the minimum requirements that it thinks companies need to fulfill to get drug-eluting stents approved.